OncoMatch/Clinical Trials/NCT06855771
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
Is NCT06855771 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies BMS-986504 for carcinoma, non-small-cell lung.
Treatment: BMS-986504 — The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: MTAP homozygous deletion
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: any prior systemic therapy
progression on prior therapies at the time of enrollment
Cannot have received: PRMT5 inhibitor
Prior treatment with a PRMT5 or MAT2A inhibitor
Cannot have received: MAT2A inhibitor
Prior treatment with a PRMT5 or MAT2A inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Alaska Oncology and Hematology · Anchorage, Alaska
- Local Institution - 0099 · Boise, Idaho
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Karmanos Cancer Institute · Detroit, Michigan
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify